Agios Pharmaceuticals, Inc. (AGIO) 10-Year Financial Performance & Capital Metrics

AGIO •

HealthcareBiotechnologyCommercial Rare Disease Biopharma

AboutAgios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Show more

Revenue $54M +48.0%
EBITDA -$472M -12.4%
Net Income -$413M -161.3%
EPS (Diluted) -7.12 -161.2%
Gross Margin 88.26% -0.4%
EBITDA Margin -873.87% +24.1%
Operating Margin -873.87% +25.1%
Net Margin -764.01% -141.4%
ROE -30.2% -152.7%
ROIC -26.57% +3.6%
Debt/Equity 0.03 -8.9%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 1.5x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-0.9%

5Y-

3Y55.97%

TTM36.26%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-159.51%

EPS CAGR

10Y-

5Y-

3Y-

TTM-161.18%

ROCE

10Y Avg-43.27%

5Y Avg-34.53%

3Y Avg-35.59%

Latest-33.76%

Peer Comparison

Commercial Rare Disease Biopharma

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CORTCorcept Therapeutics Incorporated	3.78B	35.70	43.54	12.79%	13.01%	15.3%	3.75%	0.01
BMRNBioMarin Pharmaceutical Inc.	11.86B	61.73	34.29		10.83%	5.73%	6.11%	0.10
VRTXVertex Pharmaceuticals Incorporated	126.19B	496.83	32.43	8.9%	31.35%	21.22%	2.53%	0.20
CPRXCatalyst Pharmaceuticals, Inc.	2.83B	23.08	13.74	19.78%	36.39%	22.46%	7.38%	0.00
HRMYHarmony Biosciences Holdings, Inc.	1.65B	28.54	10.53	21.51%	18.27%	18.24%	21.12%	0.02
PTCTPTC Therapeutics, Inc.	5.45B	68.19	8.76	114.51%	42.25%
BCRXBioCryst Pharmaceuticals, Inc.	1.86B	8.75	7.23	94.1%	30.16%		18.63%
RAREUltragenyx Pharmaceutical Inc.	2.26B	23.39	-3.72	29.01%	-91.95%	-35.88%		0.15

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	69.89M	43.01M	94.39M	117.91M	0	0	14.24M	26.82M	36.5M	54.03M
Revenue Growth %	18.22%	-38.46%	119.45%	24.92%	-100%	-	-	88.36%	36.07%	48.03%
Cost of Goods Sold+	220.16M	292.68M	1.4M	1.32M	18.77M	18.78M	1.7M	9.5M	4.17M	6.34M
COGS % of Revenue	315%	680.48%	1.48%	1.12%	-	-	11.97%	35.43%	11.41%	11.74%
Gross Profit+	-150.27M	-249.67M	92.99M	116.59M	-18.77M	-18.78M	12.54M	17.32M	32.33M	47.68M
Gross Margin %	-215%	-580.48%	98.52%	98.88%	-	-	88.03%	64.57%	88.59%	88.26%
Gross Profit Growth %	-81.69%	-66.15%	137.25%	25.38%	-116.1%	-0.03%	166.76%	38.15%	86.69%	47.47%
Operating Expenses+	270.88M	363.81M	455.47M	542.93M	317.14M	359.64M	401.58M	408.81M	458.07M	519.82M
OpEx % of Revenue	387.57%	845.84%	482.55%	460.45%	-	-	2820.11%	1524.09%	1255.06%	962.12%
Selling, General & Admin	50.71M	71.12M	114.14M	132.03M	106.12M	121.44M	121.67M	119.9M	156.78M	180.28M
SG&A % of Revenue	72.56%	165.36%	120.93%	111.98%	-	-	854.45%	447.02%	429.57%	333.68%
Research & Development	220.16M	292.68M	341.32M	410.89M	211.02M	256.97M	279.91M	288.9M	301.29M	339.54M
R&D % of Revenue	315%	680.48%	361.62%	348.48%	-	-	1965.66%	1077.07%	825.49%	628.44%
Other Operating Expenses	0	0	0	0	0	-18.78M	0	0	0	0
Operating Income+	-200.99M	-320.79M	-362.48M	-426.33M	-335.92M	-378.42M	-389.05M	-391.49M	-425.74M	-472.13M
Operating Margin %	-287.57%	-745.84%	-384.03%	-361.57%	-	-	-2732.07%	-1459.52%	-1166.47%	-873.87%
Operating Income Growth %	-69.32%	-59.61%	-12.99%	-17.62%	21.21%	-12.65%	-2.81%	-0.63%	-8.75%	-10.9%
EBITDA+	-195.28M	-314.36M	-355.31M	-409.71M	-317.14M	-359.64M	-380.48M	-384.86M	-420.08M	-472.13M
EBITDA Margin %	-279.4%	-730.89%	-376.44%	-347.47%	-	-	-2671.93%	-1434.83%	-1150.98%	-873.87%
EBITDA Growth %	-69.28%	-60.98%	-13.02%	-15.31%	22.59%	-13.4%	-5.8%	-1.15%	-9.15%	-12.39%
D&A (Non-Cash Add-back)	5.71M	6.43M	7.17M	16.62M	18.77M	18.78M	8.56M	6.62M	5.65M	0
EBIT	-200.99M	-320.79M	-346.03M	-411.47M	-329.31M	-356.51M	-389.05M	-391.49M	-425.74M	0
Net Interest Income+	2.51M	6.12M	16.45M	14.86M	-11.22M	836K	12.79M	33.34M	48.08M	0
Interest Income	2.51M	6.12M	16.45M	14.86M	6.61M	836K	12.79M	33.34M	48.08M	0
Interest Expense	0	0	0	0	17.83M	0	0	0	0	0
Other Income/Expense	2.51M	6.12M	16.45M	14.86M	6.61M	21.91M	157.25M	39.4M	1.14B	58.34M
Pretax Income+	-198.47M	-314.67M	-346.03M	-411.47M	-329.31M	-356.51M	-231.8M	-352.09M	717.97M	-413.8M
Pretax Margin %	-283.97%	-731.6%	-366.61%	-348.97%	-	-	-1627.82%	-1312.63%	1967.15%	-765.89%
Income Tax+	0	0	0	0	0	0	0	0	44.24M	-1.02M
Effective Tax Rate %	100%	100%	100%	100%	99.41%	-450.12%	100%	100%	93.84%	99.75%
Net Income+	-198.47M	-314.67M	-346.03M	-411.47M	-327.37M	1.6B	-231.8M	-352.09M	673.73M	-412.78M
Net Margin %	-283.97%	-731.6%	-366.61%	-348.97%	-	-	-1627.82%	-1312.63%	1845.92%	-764.01%
Net Income Growth %	-68.58%	-58.55%	-9.97%	-18.91%	20.44%	590.18%	-114.44%	-51.89%	291.35%	-161.27%
Net Income (Continuing)	-198.47M	-314.67M	-346.03M	-411.47M	-329.31M	-356.51M	-231.8M	-352.09M	673.73M	0
Discontinued Operations	0	0	0	0	1.94M	1.96B	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-5.07	-6.75	-6.03	-6.61	-4.74	-6.36	-4.23	-6.33	11.64	-7.12
EPS Growth %	-60.95%	-33.14%	10.67%	-9.62%	28.29%	-34.18%	33.49%	-49.65%	283.89%	-161.17%
EPS (Basic)	-5.07	-6.75	-6.03	-6.61	-4.74	-6.36	-4.23	-6.33	11.86	-7.12
Diluted Shares Outstanding	39.13M	46.59M	57.42M	59.99M	69M	60.45M	54.79M	55.65M	57.89M	57.97M
Basic Shares Outstanding	39.13M	46.59M	57.42M	59.99M	69M	60.45M	54.79M	55.65M	56.81M	57.97M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	559.89M	445.26M	613.78M	611.7M	636.68M	1.06B	832.77M	833.84M	965.6M	942.05M
Cash & Short-Term Investments	573.56M	567.75M	805.42M	564.88M	572.93M	1.02B	783.12M	776.93M	893.71M	854.42M
Cash Only	573.56M	567.75M	805.42M	80.93M	127.44M	203.13M	139.26M	88.2M	76.25M	89.13M
Short-Term Investments	0	0	0	483.95M	445.49M	816.89M	643.86M	688.72M	817.46M	765.29M
Accounts Receivable	8.31M	3.67M	10.44M	15.32M	0	4.38M	2.21M	2.81M	4.11M	10.58M
Days Sales Outstanding	43.42	31.14	40.38	47.42	-	-	56.54	38.24	41.09	71.46
Inventory	-32.25M	-143.81M	869K	7.33M	0	0	8.49M	19.08M	27.62M	32.92M
Days Inventory Outstanding	-	-	227.05	2.03K	-	-	1.82K	732.61	2.42K	1.89K
Other Current Assets	0	0	17.17M	0	63.75M	0	38.95M	35.02M	40.16M	44.13M
Total Non-Current Assets+	59.2M	169.14M	244.68M	279.04M	216.27M	373.5M	405.95M	103.28M	697.6M	355.17M
Property, Plant & Equipment	25.34M	24.43M	24.32M	126.11M	116.07M	104.23M	88.12M	69.79M	54.55M	41.23M
Fixed Asset Turnover	2.76x	1.76x	3.88x	0.94x	-	-	0.16x	0.38x	0.67x	1.31x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	32.25M	143.81M	220.12M	152.93M	97.61M	266.38M	313.87M	29.43M	638.32M	0
Other Non-Current Assets	1.61M	891K	238K	0	2.6M	2.9M	3.96M	4.06M	4.72M	313.94M
Total Assets+	619.09M	614.4M	858.46M	890.74M	852.95M	1.44B	1.24B	937.12M	1.66B	1.3B
Asset Turnover	0.11x	0.07x	0.11x	0.13x	-	-	0.01x	0.03x	0.02x	0.04x
Asset Growth %	47.38%	-0.76%	39.72%	3.76%	-4.24%	68.56%	-13.84%	-24.35%	77.48%	-22%
Total Current Liabilities+	88.43M	94.94M	93.5M	92.89M	94.39M	59.83M	62.63M	67.95M	81.16M	82.21M
Accounts Payable	17.11M	22.77M	17.88M	21.9M	17.72M	16.7M	18.62M	9.78M	16.64M	18.36M
Days Payables Outstanding	28.36	28.39	4.67K	6.07K	344.62	324.63	3.99K	375.6	1.46K	1.06K
Short-Term Debt	0	0	0	0	7.41M	0	0	0	0	18.39M
Deferred Revenue (Current)	190.21M	163.64M	92.52M	10.93M	0	0	0	0	0	0
Other Current Liabilities	24.32M	18.64M	22.07M	18.98M	48.91M	19.82M	12.24M	23.23M	46.86M	63.81M
Current Ratio	6.33x	4.69x	6.56x	6.59x	6.74x	17.79x	13.30x	12.27x	11.90x	11.46x
Quick Ratio	6.70x	6.20x	6.55x	6.51x	6.74x	17.79x	13.16x	11.99x	11.56x	11.06x
Cash Conversion Cycle	-	-	-4.4K	-3.99K	-	-	-2.11K	395.25	1K	909.32
Total Non-Current Liabilities+	172.07M	143.95M	77.42M	157.33M	359.06M	85.94M	75.28M	58.14M	41.09M	21.91M
Long-Term Debt	0	0	0	0	0	0	0	0	0	21.82M
Capital Lease Obligations	0	0	0	106.75M	97.79M	85.94M	72M	56.99M	40.21M	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	17.77M	18.16M	17.61M	0	261.27M	0	3.28M	1.16M	880K	90K
Total Liabilities	260.5M	238.89M	170.92M	250.21M	453.45M	145.76M	137.9M	126.1M	122.24M	104.11M
Total Debt+	0	0	0	113.66M	105.2M	97.09M	85.66M	72M	56.99M	40.21M
Net Debt	-573.56M	-567.75M	-805.42M	32.73M	-22.24M	-106.03M	-53.6M	-16.21M	-19.26M	-48.92M
Debt / Equity	-	-	-	0.18x	0.26x	0.08x	0.08x	0.09x	0.04x	0.03x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-18.84x	-	-	-	-	-
Total Equity+	358.59M	375.5M	687.54M	640.53M	399.5M	1.29B	1.1B	811.02M	1.54B	1.19B
Equity Growth %	3.9%	4.72%	83.1%	-6.84%	-37.63%	223.4%	-14.8%	-26.33%	90%	-22.57%
Book Value per Share	9.16	8.06	11.97	10.68	5.79	21.37	20.09	14.57	26.62	20.58
Total Shareholders' Equity	358.59M	375.5M	687.54M	640.53M	399.5M	1.29B	1.1B	811.02M	1.54B	1.19B
Common Stock	42K	49K	58K	68K	69K	71K	71K	72K	73K	75K
Retained Earnings	-483.15M	-798.06M	-1.1B	-1.52B	-1.84B	-238.76M	-470.56M	-822.65M	-148.92M	-561.71M
Treasury Stock	0	0	0	0	0	-802.49M	-802.49M	-802.49M	-802.49M	0
Accumulated OCI	-313K	-1.39M	-2.17M	202K	105K	-1.2M	-12.54M	-441K	-1.52M	2.19M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	38.56M	-285.23M	-304.42M	-370.62M	-290.76M	-407.32M	-309.48M	-296.06M	-389.84M	-372.98M
Operating CF Margin %	55.17%	-663.16%	-322.52%	-314.32%	-	-	-2173.3%	-1103.76%	-1068.12%	-690.34%
Operating CF Growth %	150.11%	-839.67%	-6.73%	-21.75%	21.55%	-40.09%	24.02%	4.33%	-31.68%	4.33%
Net Income	-198.47M	-314.67M	-346.03M	-411.47M	-329.31M	-356.51M	-231.8M	-352.09M	673.73M	-412.78M
Depreciation & Amortization	5.71M	6.43M	7.17M	8.09M	18.77M	9.24M	8.56M	6.62M	5.65M	5.18M
Stock-Based Compensation	42.09M	47.81M	73.36M	72.37M	0	53.51M	49.3M	44.77M	42.85M	52.55M
Deferred Taxes	0	0	0	-2.14M	0	0	0	0	0	0
Other Non-Cash Items	773K	29K	-3.82M	8.53M	17.81M	-76.74M	-119.1M	23.69M	-1.09B	-17.93M
Working Capital Changes	188.47M	-24.83M	-35.1M	-46M	1.97M	-36.82M	-16.43M	-19.06M	-19.77M	0
Change in Receivables	3.34M	1.22M	-6.1M	-3.62M	0	-4.38M	-2.21M	-604K	-1.3M	-6.47M
Change in Inventory	14.43M	-2.08M	-869K	-6.46M	-7.37M	0	-8.49M	-10.58M	-8.54M	-5.3M
Change in Payables	3.5M	5.33M	-5.49M	3.72M	3.33M	1.86M	3.44M	-8.73M	6.6M	1.75M
Cash from Investing+	-119.35M	-57.91M	-273.82M	91.44M	75.75M	1.25B	243.26M	239.57M	363.44M	377.18M
Capital Expenditures	-9.91M	-4.63M	-6.99M	-12.17M	-14.11M	-5.74M	-4.88M	-999K	-1.69M	-4.32M
CapEx % of Revenue	14.19%	10.76%	7.4%	10.32%	-	-	34.28%	3.72%	4.62%	7.99%
Acquisitions	0	0	0	-103.47M	0	0	132.75M	0	40K	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-109.44M	-53.28M	-266.84M	103.47M	-803K	1.8B	0	-16.18M	1.09B	-10M
Cash from Financing+	169.78M	285.11M	546.02M	289.61M	261.52M	-765.77M	2.35M	5.43M	14.44M	8.68M
Debt Issued (Net)	0	0	0	-113K	-336K	-578K	-331K	0	0	0
Equity Issued (Net)	1000K	1000K	1000K	1000K	1000K	-1000K	1000K	1000K	1000K	0
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	-802.49M	0	0	0	0
Other Financing	7.63M	14.86M	29.82M	12.52M	250.54M	37.3M	0	0	0	8.68M
Net Change in Cash	88.99M	-58.03M	-32.22M	10.43M	46.51M	75.69M	-63.87M	-51.05M	-11.96M	12.88M
Free Cash Flow+	28.65M	-289.86M	-311.41M	-382.79M	-304.87M	-413.06M	-314.36M	-297.06M	-391.53M	-377.29M
FCF Margin %	40.99%	-673.92%	-329.93%	-324.64%	-	-	-2207.58%	-1107.49%	-1072.73%	-698.33%
FCF Growth %	129.5%	-1111.83%	-7.43%	-22.92%	20.36%	-35.49%	23.9%	5.5%	-31.8%	3.64%
FCF per Share	0.73	-6.22	-5.42	-6.38	-4.42	-6.83	-5.74	-5.34	-6.76	-6.51
FCF Conversion (FCF/Net Income)	-0.19x	0.91x	0.88x	0.90x	0.89x	-0.25x	1.34x	0.84x	-0.58x	0.90x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	16.08M	0	1.57M	43.15M	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-56.41%	-85.73%	-65.1%	-61.97%	-62.95%	189.74%	-19.38%	-36.83%	57.29%	-30.2%
Return on Invested Capital (ROIC)	-	-	-	-115.15%	-47.96%	-36.31%	-26.13%	-31.88%	-27.57%	-26.57%
Gross Margin	-215%	-580.48%	98.52%	98.88%	-	-	88.03%	64.57%	88.59%	88.26%
Net Margin	-283.97%	-731.6%	-366.61%	-348.97%	-	-	-1627.82%	-1312.63%	1845.92%	-764.01%
Debt / Equity	-	-	-	0.18x	0.26x	0.08x	0.08x	0.09x	0.04x	0.03x
Interest Coverage	-	-	-	-	-18.84x	-	-	-	-	-
FCF Conversion	-0.19x	0.91x	0.88x	0.90x	0.89x	-0.25x	1.34x	0.84x	-0.58x	0.90x
Revenue Growth	18.22%	-38.46%	119.45%	24.92%	-100%	-	-	88.36%	36.07%	48.03%

US Stock Screener

...

Agios Pharmaceuticals, Inc. (AGIO) 10-Year Financial Performance & Capital Metrics

AGIO •

HealthcareBiotechnologyCommercial Rare Disease Biopharma

Revenue $54M +48.0%
EBITDA -$472M -12.4%
Net Income -$413M -161.3%
EPS (Diluted) -7.12 -161.2%
Gross Margin 88.26% -0.4%
EBITDA Margin -873.87% +24.1%
Operating Margin -873.87% +25.1%
Net Margin -764.01% -141.4%
ROE -30.2% -152.7%
ROIC -26.57% +3.6%
Debt/Equity 0.03 -8.9%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 1.5x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-0.9%

5Y-

3Y55.97%

TTM36.26%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-159.51%

EPS CAGR

10Y-

5Y-

3Y-

TTM-161.18%

ROCE

10Y Avg-43.27%

5Y Avg-34.53%

3Y Avg-35.59%

Latest-33.76%

Peer Comparison

Commercial Rare Disease Biopharma

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CORTCorcept Therapeutics Incorporated	3.78B	35.70	43.54	12.79%	13.01%	15.3%	3.75%	0.01
BMRNBioMarin Pharmaceutical Inc.	11.86B	61.73	34.29		10.83%	5.73%	6.11%	0.10
VRTXVertex Pharmaceuticals Incorporated	126.19B	496.83	32.43	8.9%	31.35%	21.22%	2.53%	0.20
CPRXCatalyst Pharmaceuticals, Inc.	2.83B	23.08	13.74	19.78%	36.39%	22.46%	7.38%	0.00
HRMYHarmony Biosciences Holdings, Inc.	1.65B	28.54	10.53	21.51%	18.27%	18.24%	21.12%	0.02
PTCTPTC Therapeutics, Inc.	5.45B	68.19	8.76	114.51%	42.25%
BCRXBioCryst Pharmaceuticals, Inc.	1.86B	8.75	7.23	94.1%	30.16%		18.63%
RAREUltragenyx Pharmaceutical Inc.	2.26B	23.39	-3.72	29.01%	-91.95%	-35.88%		0.15

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	69.89M	43.01M	94.39M	117.91M	0	0	14.24M	26.82M	36.5M	54.03M
Revenue Growth %	18.22%	-38.46%	119.45%	24.92%	-100%	-	-	88.36%	36.07%	48.03%
Cost of Goods Sold+	220.16M	292.68M	1.4M	1.32M	18.77M	18.78M	1.7M	9.5M	4.17M	6.34M
COGS % of Revenue	315%	680.48%	1.48%	1.12%	-	-	11.97%	35.43%	11.41%	11.74%
Gross Profit+	-150.27M	-249.67M	92.99M	116.59M	-18.77M	-18.78M	12.54M	17.32M	32.33M	47.68M
Gross Margin %	-215%	-580.48%	98.52%	98.88%	-	-	88.03%	64.57%	88.59%	88.26%
Gross Profit Growth %	-81.69%	-66.15%	137.25%	25.38%	-116.1%	-0.03%	166.76%	38.15%	86.69%	47.47%
Operating Expenses+	270.88M	363.81M	455.47M	542.93M	317.14M	359.64M	401.58M	408.81M	458.07M	519.82M
OpEx % of Revenue	387.57%	845.84%	482.55%	460.45%	-	-	2820.11%	1524.09%	1255.06%	962.12%
Selling, General & Admin	50.71M	71.12M	114.14M	132.03M	106.12M	121.44M	121.67M	119.9M	156.78M	180.28M
SG&A % of Revenue	72.56%	165.36%	120.93%	111.98%	-	-	854.45%	447.02%	429.57%	333.68%
Research & Development	220.16M	292.68M	341.32M	410.89M	211.02M	256.97M	279.91M	288.9M	301.29M	339.54M
R&D % of Revenue	315%	680.48%	361.62%	348.48%	-	-	1965.66%	1077.07%	825.49%	628.44%
Other Operating Expenses	0	0	0	0	0	-18.78M	0	0	0	0
Operating Income+	-200.99M	-320.79M	-362.48M	-426.33M	-335.92M	-378.42M	-389.05M	-391.49M	-425.74M	-472.13M
Operating Margin %	-287.57%	-745.84%	-384.03%	-361.57%	-	-	-2732.07%	-1459.52%	-1166.47%	-873.87%
Operating Income Growth %	-69.32%	-59.61%	-12.99%	-17.62%	21.21%	-12.65%	-2.81%	-0.63%	-8.75%	-10.9%
EBITDA+	-195.28M	-314.36M	-355.31M	-409.71M	-317.14M	-359.64M	-380.48M	-384.86M	-420.08M	-472.13M
EBITDA Margin %	-279.4%	-730.89%	-376.44%	-347.47%	-	-	-2671.93%	-1434.83%	-1150.98%	-873.87%
EBITDA Growth %	-69.28%	-60.98%	-13.02%	-15.31%	22.59%	-13.4%	-5.8%	-1.15%	-9.15%	-12.39%
D&A (Non-Cash Add-back)	5.71M	6.43M	7.17M	16.62M	18.77M	18.78M	8.56M	6.62M	5.65M	0
EBIT	-200.99M	-320.79M	-346.03M	-411.47M	-329.31M	-356.51M	-389.05M	-391.49M	-425.74M	0
Net Interest Income+	2.51M	6.12M	16.45M	14.86M	-11.22M	836K	12.79M	33.34M	48.08M	0
Interest Income	2.51M	6.12M	16.45M	14.86M	6.61M	836K	12.79M	33.34M	48.08M	0
Interest Expense	0	0	0	0	17.83M	0	0	0	0	0
Other Income/Expense	2.51M	6.12M	16.45M	14.86M	6.61M	21.91M	157.25M	39.4M	1.14B	58.34M
Pretax Income+	-198.47M	-314.67M	-346.03M	-411.47M	-329.31M	-356.51M	-231.8M	-352.09M	717.97M	-413.8M
Pretax Margin %	-283.97%	-731.6%	-366.61%	-348.97%	-	-	-1627.82%	-1312.63%	1967.15%	-765.89%
Income Tax+	0	0	0	0	0	0	0	0	44.24M	-1.02M
Effective Tax Rate %	100%	100%	100%	100%	99.41%	-450.12%	100%	100%	93.84%	99.75%
Net Income+	-198.47M	-314.67M	-346.03M	-411.47M	-327.37M	1.6B	-231.8M	-352.09M	673.73M	-412.78M
Net Margin %	-283.97%	-731.6%	-366.61%	-348.97%	-	-	-1627.82%	-1312.63%	1845.92%	-764.01%
Net Income Growth %	-68.58%	-58.55%	-9.97%	-18.91%	20.44%	590.18%	-114.44%	-51.89%	291.35%	-161.27%
Net Income (Continuing)	-198.47M	-314.67M	-346.03M	-411.47M	-329.31M	-356.51M	-231.8M	-352.09M	673.73M	0
Discontinued Operations	0	0	0	0	1.94M	1.96B	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-5.07	-6.75	-6.03	-6.61	-4.74	-6.36	-4.23	-6.33	11.64	-7.12
EPS Growth %	-60.95%	-33.14%	10.67%	-9.62%	28.29%	-34.18%	33.49%	-49.65%	283.89%	-161.17%
EPS (Basic)	-5.07	-6.75	-6.03	-6.61	-4.74	-6.36	-4.23	-6.33	11.86	-7.12
Diluted Shares Outstanding	39.13M	46.59M	57.42M	59.99M	69M	60.45M	54.79M	55.65M	57.89M	57.97M
Basic Shares Outstanding	39.13M	46.59M	57.42M	59.99M	69M	60.45M	54.79M	55.65M	56.81M	57.97M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	559.89M	445.26M	613.78M	611.7M	636.68M	1.06B	832.77M	833.84M	965.6M	942.05M
Cash & Short-Term Investments	573.56M	567.75M	805.42M	564.88M	572.93M	1.02B	783.12M	776.93M	893.71M	854.42M
Cash Only	573.56M	567.75M	805.42M	80.93M	127.44M	203.13M	139.26M	88.2M	76.25M	89.13M
Short-Term Investments	0	0	0	483.95M	445.49M	816.89M	643.86M	688.72M	817.46M	765.29M
Accounts Receivable	8.31M	3.67M	10.44M	15.32M	0	4.38M	2.21M	2.81M	4.11M	10.58M
Days Sales Outstanding	43.42	31.14	40.38	47.42	-	-	56.54	38.24	41.09	71.46
Inventory	-32.25M	-143.81M	869K	7.33M	0	0	8.49M	19.08M	27.62M	32.92M
Days Inventory Outstanding	-	-	227.05	2.03K	-	-	1.82K	732.61	2.42K	1.89K
Other Current Assets	0	0	17.17M	0	63.75M	0	38.95M	35.02M	40.16M	44.13M
Total Non-Current Assets+	59.2M	169.14M	244.68M	279.04M	216.27M	373.5M	405.95M	103.28M	697.6M	355.17M
Property, Plant & Equipment	25.34M	24.43M	24.32M	126.11M	116.07M	104.23M	88.12M	69.79M	54.55M	41.23M
Fixed Asset Turnover	2.76x	1.76x	3.88x	0.94x	-	-	0.16x	0.38x	0.67x	1.31x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	32.25M	143.81M	220.12M	152.93M	97.61M	266.38M	313.87M	29.43M	638.32M	0
Other Non-Current Assets	1.61M	891K	238K	0	2.6M	2.9M	3.96M	4.06M	4.72M	313.94M
Total Assets+	619.09M	614.4M	858.46M	890.74M	852.95M	1.44B	1.24B	937.12M	1.66B	1.3B
Asset Turnover	0.11x	0.07x	0.11x	0.13x	-	-	0.01x	0.03x	0.02x	0.04x
Asset Growth %	47.38%	-0.76%	39.72%	3.76%	-4.24%	68.56%	-13.84%	-24.35%	77.48%	-22%
Total Current Liabilities+	88.43M	94.94M	93.5M	92.89M	94.39M	59.83M	62.63M	67.95M	81.16M	82.21M
Accounts Payable	17.11M	22.77M	17.88M	21.9M	17.72M	16.7M	18.62M	9.78M	16.64M	18.36M
Days Payables Outstanding	28.36	28.39	4.67K	6.07K	344.62	324.63	3.99K	375.6	1.46K	1.06K
Short-Term Debt	0	0	0	0	7.41M	0	0	0	0	18.39M
Deferred Revenue (Current)	190.21M	163.64M	92.52M	10.93M	0	0	0	0	0	0
Other Current Liabilities	24.32M	18.64M	22.07M	18.98M	48.91M	19.82M	12.24M	23.23M	46.86M	63.81M
Current Ratio	6.33x	4.69x	6.56x	6.59x	6.74x	17.79x	13.30x	12.27x	11.90x	11.46x
Quick Ratio	6.70x	6.20x	6.55x	6.51x	6.74x	17.79x	13.16x	11.99x	11.56x	11.06x
Cash Conversion Cycle	-	-	-4.4K	-3.99K	-	-	-2.11K	395.25	1K	909.32
Total Non-Current Liabilities+	172.07M	143.95M	77.42M	157.33M	359.06M	85.94M	75.28M	58.14M	41.09M	21.91M
Long-Term Debt	0	0	0	0	0	0	0	0	0	21.82M
Capital Lease Obligations	0	0	0	106.75M	97.79M	85.94M	72M	56.99M	40.21M	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	17.77M	18.16M	17.61M	0	261.27M	0	3.28M	1.16M	880K	90K
Total Liabilities	260.5M	238.89M	170.92M	250.21M	453.45M	145.76M	137.9M	126.1M	122.24M	104.11M
Total Debt+	0	0	0	113.66M	105.2M	97.09M	85.66M	72M	56.99M	40.21M
Net Debt	-573.56M	-567.75M	-805.42M	32.73M	-22.24M	-106.03M	-53.6M	-16.21M	-19.26M	-48.92M
Debt / Equity	-	-	-	0.18x	0.26x	0.08x	0.08x	0.09x	0.04x	0.03x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-18.84x	-	-	-	-	-
Total Equity+	358.59M	375.5M	687.54M	640.53M	399.5M	1.29B	1.1B	811.02M	1.54B	1.19B
Equity Growth %	3.9%	4.72%	83.1%	-6.84%	-37.63%	223.4%	-14.8%	-26.33%	90%	-22.57%
Book Value per Share	9.16	8.06	11.97	10.68	5.79	21.37	20.09	14.57	26.62	20.58
Total Shareholders' Equity	358.59M	375.5M	687.54M	640.53M	399.5M	1.29B	1.1B	811.02M	1.54B	1.19B
Common Stock	42K	49K	58K	68K	69K	71K	71K	72K	73K	75K
Retained Earnings	-483.15M	-798.06M	-1.1B	-1.52B	-1.84B	-238.76M	-470.56M	-822.65M	-148.92M	-561.71M
Treasury Stock	0	0	0	0	0	-802.49M	-802.49M	-802.49M	-802.49M	0
Accumulated OCI	-313K	-1.39M	-2.17M	202K	105K	-1.2M	-12.54M	-441K	-1.52M	2.19M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	38.56M	-285.23M	-304.42M	-370.62M	-290.76M	-407.32M	-309.48M	-296.06M	-389.84M	-372.98M
Operating CF Margin %	55.17%	-663.16%	-322.52%	-314.32%	-	-	-2173.3%	-1103.76%	-1068.12%	-690.34%
Operating CF Growth %	150.11%	-839.67%	-6.73%	-21.75%	21.55%	-40.09%	24.02%	4.33%	-31.68%	4.33%
Net Income	-198.47M	-314.67M	-346.03M	-411.47M	-329.31M	-356.51M	-231.8M	-352.09M	673.73M	-412.78M
Depreciation & Amortization	5.71M	6.43M	7.17M	8.09M	18.77M	9.24M	8.56M	6.62M	5.65M	5.18M
Stock-Based Compensation	42.09M	47.81M	73.36M	72.37M	0	53.51M	49.3M	44.77M	42.85M	52.55M
Deferred Taxes	0	0	0	-2.14M	0	0	0	0	0	0
Other Non-Cash Items	773K	29K	-3.82M	8.53M	17.81M	-76.74M	-119.1M	23.69M	-1.09B	-17.93M
Working Capital Changes	188.47M	-24.83M	-35.1M	-46M	1.97M	-36.82M	-16.43M	-19.06M	-19.77M	0
Change in Receivables	3.34M	1.22M	-6.1M	-3.62M	0	-4.38M	-2.21M	-604K	-1.3M	-6.47M
Change in Inventory	14.43M	-2.08M	-869K	-6.46M	-7.37M	0	-8.49M	-10.58M	-8.54M	-5.3M
Change in Payables	3.5M	5.33M	-5.49M	3.72M	3.33M	1.86M	3.44M	-8.73M	6.6M	1.75M
Cash from Investing+	-119.35M	-57.91M	-273.82M	91.44M	75.75M	1.25B	243.26M	239.57M	363.44M	377.18M
Capital Expenditures	-9.91M	-4.63M	-6.99M	-12.17M	-14.11M	-5.74M	-4.88M	-999K	-1.69M	-4.32M
CapEx % of Revenue	14.19%	10.76%	7.4%	10.32%	-	-	34.28%	3.72%	4.62%	7.99%
Acquisitions	0	0	0	-103.47M	0	0	132.75M	0	40K	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-109.44M	-53.28M	-266.84M	103.47M	-803K	1.8B	0	-16.18M	1.09B	-10M
Cash from Financing+	169.78M	285.11M	546.02M	289.61M	261.52M	-765.77M	2.35M	5.43M	14.44M	8.68M
Debt Issued (Net)	0	0	0	-113K	-336K	-578K	-331K	0	0	0
Equity Issued (Net)	1000K	1000K	1000K	1000K	1000K	-1000K	1000K	1000K	1000K	0
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	-802.49M	0	0	0	0
Other Financing	7.63M	14.86M	29.82M	12.52M	250.54M	37.3M	0	0	0	8.68M
Net Change in Cash	88.99M	-58.03M	-32.22M	10.43M	46.51M	75.69M	-63.87M	-51.05M	-11.96M	12.88M
Free Cash Flow+	28.65M	-289.86M	-311.41M	-382.79M	-304.87M	-413.06M	-314.36M	-297.06M	-391.53M	-377.29M
FCF Margin %	40.99%	-673.92%	-329.93%	-324.64%	-	-	-2207.58%	-1107.49%	-1072.73%	-698.33%
FCF Growth %	129.5%	-1111.83%	-7.43%	-22.92%	20.36%	-35.49%	23.9%	5.5%	-31.8%	3.64%
FCF per Share	0.73	-6.22	-5.42	-6.38	-4.42	-6.83	-5.74	-5.34	-6.76	-6.51
FCF Conversion (FCF/Net Income)	-0.19x	0.91x	0.88x	0.90x	0.89x	-0.25x	1.34x	0.84x	-0.58x	0.90x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	16.08M	0	1.57M	43.15M	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-56.41%	-85.73%	-65.1%	-61.97%	-62.95%	189.74%	-19.38%	-36.83%	57.29%	-30.2%
Return on Invested Capital (ROIC)	-	-	-	-115.15%	-47.96%	-36.31%	-26.13%	-31.88%	-27.57%	-26.57%
Gross Margin	-215%	-580.48%	98.52%	98.88%	-	-	88.03%	64.57%	88.59%	88.26%
Net Margin	-283.97%	-731.6%	-366.61%	-348.97%	-	-	-1627.82%	-1312.63%	1845.92%	-764.01%
Debt / Equity	-	-	-	0.18x	0.26x	0.08x	0.08x	0.09x	0.04x	0.03x
Interest Coverage	-	-	-	-	-18.84x	-	-	-	-	-
FCF Conversion	-0.19x	0.91x	0.88x	0.90x	0.89x	-0.25x	1.34x	0.84x	-0.58x	0.90x
Revenue Growth	18.22%	-38.46%	119.45%	24.92%	-100%	-	-	88.36%	36.07%	48.03%

Agios Pharmaceuticals, Inc. (AGIO) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare AGIO vs Peers

vs VRTX

vs ASND

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Agios Pharmaceuticals, Inc. (AGIO) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare AGIO vs Peers

vs VRTX

vs ASND

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios